Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA

$ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )$

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France

Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )

Diverse T lymphocyte population fights leukaemia more effectively

Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany

Diverse T lymphocyte population fights leukaemia more effectively ( Dr Michaela Kotrova - University Hospital Schleswig-Holstein, Kiel, Germany )

Personalised medicine for rare cancers

Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy

Personalised medicine for rare cancers ( Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy )

T-VEC and checkpoint therapy for melanoma

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

T-VEC and checkpoint therapy for melanoma ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Treating advanced melanoma with ipilimumab and HF10

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Treating advanced melanoma with ipilimumab and HF10 ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers ( Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA )

Immunotherapy may slow the growth of malignant pleural mesothelioma

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy may slow the growth of malignant pleural mesothelioma ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

Immunotherapy for mesothelioma could be on the horizon

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy for mesothelioma could be on the horizon ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

CAR T-cell therapy can be used to send multiple myeloma into lasting remission

Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China

CAR T-cell therapy can be used to send multiple myeloma into lasting remission ( Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China )

New personalised therapies for lung cancer

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

New personalised therapies for lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )

Findings of a phase I/II study of nivolumab in patients with virus-associated...

Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours ( Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France )

More from ecancer